Citadel Advisors
EWTX icon

Citadel Advisors’s Edgewise Therapeutics EWTX Stock Holding History

Citadel Advisors’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$219K Sell
5,400
-39,200
-88% -$1.35M ﹤0.01% 11851
2026
Q1 		$1.4M Buy
44,600
+17,900
+67% +$516K ﹤0.01% 6868
2025
Q4 		$663K Buy
26,700
+7,500
+39% +$151K ﹤0.01% 8334
2025
Q3 		$311K Sell
19,200
-16,300
-46% -$231K ﹤0.01% 10283
2025
Q2 		$465K Buy
35,500
+2,200
+7% +$31.7K ﹤0.01% 8801
2025
Q1 		$733K Sell
33,300
-55,700
-63% -$1.46M ﹤0.01% 7641
2024
Q4 		$2.38M Buy
89,000
+26,200
+42% +$834K ﹤0.01% 5274
2024
Q3 		$1.68M Buy
62,800
+57,500
+1,085% +$1.14M ﹤0.01% 5852
2024
Q2 		$95.5K Sell
5,300
-9,500
-64% -$166K ﹤0.01% 10982
2024
Q1 		$270K Buy
14,800
+8,200
+124% +$130K ﹤0.01% 9698
2023
Q4 		$72.2K Buy
6,600
+6,300
+2,100% +$44.2K ﹤0.01% 11351
2023
Q3 		$1.72K Sell
300
-1,700
-85% -$11.6K ﹤0.01% 13821
2023
Q2 		$15.5K Sell
2,000
-3,700
-65% -$31.2K ﹤0.01% 12943
2023
Q1 		$38K Buy
5,700
+100
+2% +$927 ﹤0.01% 12479
2022
Q4 		$50.1K Buy
+5,600
New +$52.5K ﹤0.01% 12140

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors's EWTX Position: Q2 2026 in Review

Citadel Advisors increased its Edgewise Therapeutics (EWTX) stake by 9.5% in Q2 2026, buying an estimated $1.4M and bringing the position to 469,707 shares worth $19.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2652.

Citadel Advisors first reported a position in EWTX in Q1 2021 and has held it in 22 quarters since. The position peaked at $77.4M in Q1 2021. 226 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Citadel Advisors held 469,707 shares of Edgewise Therapeutics worth $19.1M as of Q2 2026.
  • Citadel Advisors bought 40,675 Edgewise Therapeutics shares in Q2 2026, an estimated $1.4M.
  • Edgewise Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #2652 holding.
  • Citadel Advisors first reported a position in Edgewise Therapeutics in Q1 2021 and has held it in 22 quarters since.
  • Citadel Advisors's Edgewise Therapeutics position peaked at $77.4M in Q1 2021.
  • 226 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.